试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-10-30
A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
编号:NCT01114503登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:Otelixizumab - low dose、Otelixizumab - medium low dose、Otelixizumab - medium high dose、Otelixizumab - high dose
登记的停止原因(原文):Clinical study in Graves' ophthalmopathy terminated until there is a better understanding of an efficacious dose with Otelixizumab from other clinical studies.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-10-30
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
编号:NCT01195779登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:GSK Bio's influenza vaccine GSK2584786A, different formulations、GSK Bio's influenza vaccine GSK2321138A、Fluarix™
登记的停止原因(原文):The study was terminated for logistic reasons not related to safety or efficacy of the vaccine.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-10-30
Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus
编号:NCT01222078登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:otelixizumab
登记的停止原因(原文):A Phase 3 study recently reported and demonstrated that the dose of otelixizumab in OTX113390 is not effective.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-10-30
A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children
编号:NCT01458418登记状态:提前终止企业 / 申办者:Children's Mercy Hospital Kansas City
药物 / 成分:Montelukast、placebo、5 mg Montelukast
登记的停止原因(原文):Inability to complete enrollment due to difficulty in finding subjects
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-10-30
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
编号:NCT01668654登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:retigabine/ezogabine
登记的停止原因(原文):FDA placed a clinical hold on the Pediatric Program requiring retigabine discontinuation in subjects; early termination allows for timely reporting of results.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-10-30
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
编号:NCT02757391登记状态:提前终止企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:Adoptive Immunotherapy、Aldesleukin、Cyclophosphamide、Laboratory Biomarker Analysis
登记的停止原因(原文):Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-10-30
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
编号:NCT02793154登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:Exenatide、Albiglutide
登记的停止原因(原文):Early termination due to insufficient enrollment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-10-30
A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects
编号:NCT02802514登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:Albiglutide 50mg、Albiglutide matching placebo、Exenatide 10microgram、Exenatide placebo (saline)
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-10-30
Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis
编号:NCT02965599登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:GSK3117391、Placebo
登记的停止原因(原文):The study was terminated following an internal review of the company's current research and development portfolio.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-10-29
Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)
编号:NCT00759876登记状态:提前终止企业 / 申办者:PTC Therapeutics
药物 / 成分:Ataluren
登记的停止原因(原文):Terminated early because similar study with Ataluren (PTC124-GD-007-DMD; NCT00592553) exhibited lack of efficacy at the high dose (not due to safety concerns).
查看官方原始记录 ↗